Exicure Q2 10-Q: Cash Drops to $1.7M, Nasdaq Equity Deficiency, Going Concern Doubt
XCUR is trading near its 52-week low of $1.18 (6.8% above the low).
Summary
Exicure's Q2 2026 10-Q shows cash down to $1.7M, stockholders' equity below Nasdaq's minimum, and a going concern warning. The company amended a $1M milestone payment to be paid in stock and faces ongoing legal disputes.
Key Events · Earnings and Guidance · XCUR
-
Cash Drops to $1.7M
Cash and cash equivalents fell to $1.7 million as of June 30, 2026, from $3.7 million at December 31, 2025, with net cash used in operations of $2.0 million for the six months.
-
Nasdaq Equity Deficiency
Stockholders' equity declined to $0.977 million, below Nasdaq's $2.5 million minimum. The company received a deficiency notice on June 5, 2026, and submitted a Plan of Compliance on July 30, 2026.
-
Going Concern Warning
Management states substantial doubt about the company's ability to continue as a going concern within one year, citing insufficient cash to fund operations for the next twelve months.
-
Milestone Payment Amended to Stock
The company could not pay the $1.0 million Milestone 1 payment to GPCR on time and amended the terms to satisfy the obligation through issuance of common stock, causing further dilution.
Analysis · XCUR · Life Sciences
Exicure's Q2 2026 report confirms the company is in severe financial distress. Cash fell to $1.7 million from $3.7 million at year-end, and stockholders' equity dropped to $0.977 million, triggering a Nasdaq deficiency notice. The company states there is substantial doubt about its ability to continue as a going concern and may seek bankruptcy protection. Additionally, the company could not pay a $1.0 million milestone to GPCR and will satisfy it with stock, further diluting shareholders. The company also faces a $0.7 million unpaid rent lawsuit and settled a former employee lawsuit for $425,000. This filing materially updates the prior quarter's distress with new adverse developments.
At the time of this filing, XCUR was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $1.18 to $9.48. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.